Geode Capital Management, LLC Neurocrine Biosciences Inc Transaction History

Geode Capital Management, LLC

$1.07 Trillion
Q1 2024

A detailed history of Geode Capital Management, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,713,714 shares of NBIX stock, worth $232 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,713,714

Previous 1,623,124 5.58%

Holding current value

$232 Million

Previous $214 Million 10.52%

% of portfolio

0.02%

Previous 0.02%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $11.8 Million - $13 Million	90,590 Added 5.58%	1,713,714 $236 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $7.27 Million - $9.09 Million	68,494 Added 4.41%	1,623,124 $214 Million
Q3 2023 Nov 13, 2023	BUY	$94.02 - $117.1 $2.94 Million - $3.66 Million	31,222 Added 2.05%	1,554,630 $175 Million
Q2 2023 Aug 11, 2023	BUY	$89.53 - $104.87 $7.85 Million - $9.19 Million	87,671 Added 6.11%	1,523,408 $144 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $4.43 Million - $5.79 Million	47,042 Added 3.39%	1,435,737 $145 Million

Q4 2022 Feb 13, 2023	BUY	$106.72 - $127.06 $7.58 Million - $9.02 Million	71,001 Added 5.39%	1,388,695 $166 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $3.41 Million - $4 Million	37,089 Added 2.9%	1,317,694 $140 Million
Q2 2022 Aug 12, 2022	SELL	$75.79 - $100.07 $260,262 - $343,640	-3,434 Reduced 0.27%	1,280,605 $125 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $3.37 Million - $4.41 Million	46,491 Added 3.76%	1,284,039 $120 Million
Q4 2021 Feb 11, 2022	BUY	$79.65 - $106.22 $2.02 Million - $2.69 Million	25,327 Added 2.09%	1,237,548 $105 Million
Q3 2021 Nov 12, 2021	BUY	$86.18 - $99.03 $783,117 - $899,885	9,087 Added 0.76%	1,212,221 $116 Million
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $2.11 Million - $2.42 Million	23,626 Added 2.0%	1,203,134 $117 Million
Q1 2021 May 12, 2021	BUY	$87.57 - $119.4 $4.72 Million - $6.44 Million	53,898 Added 4.79%	1,179,508 $115 Million
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $5.13 Million - $6.39 Million	59,008 Added 5.53%	1,125,610 $108 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $4.08 Million - $5.73 Million	-42,408 Reduced 3.82%	1,066,602 $102 Million
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $3.1 Million - $4.74 Million	36,376 Added 3.39%	1,109,010 $135 Million
Q1 2020 May 14, 2020	BUY	$75.11 - $113.76 $2.81 Million - $4.26 Million	37,404 Added 3.61%	1,072,634 $92.8 Million
Q4 2019 Feb 13, 2020	BUY	$86.8 - $118.57 $4.52 Million - $6.17 Million	52,052 Added 5.29%	1,035,230 $111 Million
Q3 2019 Nov 12, 2019	BUY	$83.82 - $101.5 $574,502 - $695,681	6,854 Added 0.7%	983,178 $88.6 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $1.96 Million - $2.48 Million	27,195 Added 2.87%	976,324 $82.4 Million
Q1 2019 May 14, 2019	BUY	$69.31 - $91.53 $2.9 Million - $3.83 Million	41,837 Added 4.61%	949,129 $83.6 Million
Q4 2018 Feb 13, 2019	BUY	$68.32 - $124.36 $2.49 Million - $4.54 Million	36,508 Added 4.19%	907,292 $64.8 Million
Q3 2018 Nov 13, 2018	BUY	$98.88 - $125.85 $3.32 Million - $4.23 Million	33,581 Added 4.01%	870,784 $107 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $3.9 Million - $5.5 Million	51,850 Added 6.6%	837,203 $82.2 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.71 Million - $2.08 Million	22,518 Added 2.95%	785,353 $65.1 Million
Q4 2017 Feb 13, 2018	BUY	$58.53 - $77.59 $722,669 - $958,003	12,347 Added 1.65%	762,835 $59.2 Million
Q3 2017 Nov 14, 2017	BUY	$47.97 - $61.28 $1.64 Million - $2.09 Million	34,097 Added 4.76%	750,488 $46 Million
Q2 2017 Aug 14, 2017	BUY	N/A	716,391	716,391 $33 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

94.4M

Call Options Held

505K

Put Options Held

343K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Neurocrine Biosciences Inc Transaction History